Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swedish (OMX) Healthcare Sector Analysis

UpdatedMar 15, 2026
DataAggregated Company Financials
Companies150
  • 7D-0.7%
  • 3M-5.9%
  • 1Y-6.7%
  • YTD-5.5%

The Healthcare is pretty flat in the last 7 days, but Sectra has stood out, gaining 9.4%. As for the longer term, the industry has declined 6.7% in the last year. Earnings are forecast to grow by 25% annually.

Sector Valuation and Performance

Has the Swedish Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sun, 15 Mar 2026SEK 551.6bSEK 228.9b-SEK 2,899,721,423.9230.3x-190.2x2.4x
Tue, 10 Feb 2026SEK 582.4bSEK 229.2b-SEK 1,818,895,407.9733.5x-320.2x2.5x
Thu, 08 Jan 2026SEK 595.8bSEK 230.2bSEK 3.7b42.5x162.3x2.6x
Sat, 06 Dec 2025SEK 595.3bSEK 230.8bSEK 3.6b42.6x167.7x2.6x
Mon, 03 Nov 2025SEK 610.3bSEK 228.3bSEK 3.3b46.3x182.9x2.7x
Wed, 01 Oct 2025SEK 602.7bSEK 227.2bSEK 6.6b43.8x91.2x2.7x
Fri, 29 Aug 2025SEK 630.1bSEK 227.0bSEK 6.5b46.9x97.5x2.8x
Sun, 27 Jul 2025SEK 639.6bSEK 226.9bSEK 6.5b54.5x97.8x2.8x
Tue, 24 Jun 2025SEK 597.9bSEK 226.8bSEK 5.9b42.4x102x2.6x
Thu, 22 May 2025SEK 609.9bSEK 224.8bSEK 5.6b42.8x109.1x2.7x
Sat, 19 Apr 2025SEK 547.9bSEK 221.4bSEK 5.2b32.3x106.1x2.5x
Mon, 17 Mar 2025SEK 558.7bSEK 206.3bSEK 4.9b37.2x114x2.7x
Wed, 12 Feb 2025SEK 597.8bSEK 204.6bSEK 1.9b42x306.6x2.9x
Fri, 10 Jan 2025SEK 581.4bSEK 202.7b-SEK 2,498,772,099.0841.1x-232.7x2.9x
Sun, 08 Dec 2024SEK 574.5bSEK 202.6b-SEK 2,458,596,674.2638.4x-233.7x2.8x
Tue, 05 Nov 2024SEK 529.8bSEK 200.1b-SEK 2,878,137,098.3537.3x-184.1x2.6x
Thu, 03 Oct 2024SEK 611.2bSEK 200.1b-SEK 2,795,616,063.1739.4x-218.6x3.1x
Sat, 31 Aug 2024SEK 616.5bSEK 200.0b-SEK 2,747,933,248.0339.2x-224.3x3.1x
Mon, 29 Jul 2024SEK 593.0bSEK 200.1b-SEK 2,850,286,974.0841.4x-208.1x3x
Wed, 26 Jun 2024SEK 559.9bSEK 195.5b-SEK 3,182,980,678.0236.6x-175.9x2.9x
Fri, 24 May 2024SEK 552.4bSEK 196.2b-SEK 2,803,697,309.8236.6x-197x2.8x
Sun, 21 Apr 2024SEK 509.5bSEK 193.1b-SEK 3,154,419,283.3344.5x-161.5x2.6x
Tue, 19 Mar 2024SEK 516.3bSEK 192.4b-SEK 3,668,940,848.1443.8x-140.7x2.7x
Thu, 15 Feb 2024SEK 514.4bSEK 191.2b-SEK 4,145,018,101.6349.1x-124.1x2.7x
Sat, 13 Jan 2024SEK 558.9bSEK 191.5b-SEK 965,181,563.0048.1x-579.1x2.9x
Mon, 11 Dec 2023SEK 506.7bSEK 190.4b-SEK 1,067,818,862.0051.2x-474.5x2.7x
Wed, 08 Nov 2023SEK 460.7bSEK 190.1b-SEK 1,032,989,646.0047x-446x2.4x
Fri, 06 Oct 2023SEK 441.8bSEK 185.1b-SEK 2,029,998,059.0034.4x-217.6x2.4x
Sun, 03 Sep 2023SEK 467.5bSEK 185.6b-SEK 1,979,325,492.0038.7x-236.2x2.5x
Tue, 01 Aug 2023SEK 481.6bSEK 183.7b-SEK 982,883,275.0040.4x-490x2.6x
Thu, 29 Jun 2023SEK 467.1bSEK 179.3b-SEK 795,555,695.0044.9x-587.1x2.6x
Sat, 27 May 2023SEK 515.5bSEK 178.7b-SEK 592,621,923.0044.1x-869.9x2.9x
Mon, 24 Apr 2023SEK 511.2bSEK 173.1b-SEK 1,503,140,075.0035x-340.1x3x
Wed, 22 Mar 2023SEK 481.6bSEK 172.2b-SEK 1,414,392,878.0036.2x-340.5x2.8x
Price to Earnings Ratio

-340.5x


Total Market Cap: SEK 481.6bTotal Earnings: -SEK 1,414,392,878.00Total Revenue: SEK 172.2bTotal Market Cap vs Earnings and Revenue0%0%0%
Swedish Healthcare Sector Price to Earnings3Y Average -166.4x202420252026
Current Industry PE
  • Investors are pessimistic on the Swedish Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The 3-year average PS ratio of 2.7x is higher than the industry's current PS ratio of 2.4x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have deteriorated over the last three years.
  • Meanwhile revenues for these companies have grown 9.9% per year.
  • This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has caused losses to expand.

Industry Trends

Which industries have driven the changes within the Swedish Healthcare sector?

SE Market-1.13%
Healthcare-0.68%
Healthtech7.34%
Biotech-0.25%
Healthcare Services-1.03%
Pharma-1.65%
Life Sciences-2.69%
Medical Equipment-3.49%
Industry PE
  • Investors are most optimistic about the Healthtech industry which is trading above its 3-year average PE ratio of 115x.
    • Analysts are expecting annual earnings growth of 20.3%, which is higher than its past year's earnings growth of 1.5% per year.
Forecasted Growth
  • Analysts are most optimistic on the Pharma industry, expecting annual earnings growth of 35% over the next 5 years.
  • This is better than its past earnings growth rate of 14% per year.
  • In contrast, the Life Sciences industry is expected to see its earnings grow by 17% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
SECT B SectraSEK 232.009.4%
+SEK 3.9b		-5.5%PE83.2x
VIMIAN Vimian GroupSEK 26.123.7%
+SEK 486.9m		-31.7%PE40.9x
MVIR MedivirSEK 2.4356.4%
+SEK 471.9m		64.2%PS154x
BIOA B BioArcticSEK 302.401.2%
+SEK 319.4m		43.3%PE26.2x
BIOG B BioGaiaSEK 113.402.8%
+SEK 313.6m		-1.7%PE34.5x

Latest News

SCIB
SEK 0.29
SciBase Holding
7D
8.3%
1Y
-28.4%
GETI B
SEK 188.95
Getinge
7D
-3.5%
1Y
-15.5%

GETI B: Slightly Higher Dividend Will Still Leave P/E Looking Stretched

Analysts have kept their SEK 170.97 price target for Getinge broadly unchanged, citing only marginal tweaks to assumptions around the discount rate, revenue growth, profit margin and future P/E that do not materially alter their overall view of the shares. What's in the News Getinge AB has a proposed dividend of SEK 4.75 per share, compared with SEK 4.60 previously (Key Developments).
MVIR
SEK 2.43
Medivir
7D
56.4%
1Y
64.2%

Rare Disease And Liver Cancer Setbacks Will Test This High Risk Pipeline Story

Catalysts About Medivir Medivir is a research based pharmaceutical company focused on developing first in class therapies for oncology and rare bone disorders. What are the underlying business or industry changes driving this perspective?
SECT B
SEK 232.00
Sectra
7D
9.4%
1Y
-5.5%
ATT
SEK 99.80
Attendo
7D
-3.9%
1Y
57.2%

ATT: Future Dividend And Cash Returns Will Support Steady Prospects

Narrative Update on Attendo Analysts have kept Attendo's fair value estimate steady at SEK 110, with only minor adjustments to inputs such as the discount rate and assumed future P/E. This reflects fine tuning of their valuation rather than a shift in overall view.
BIOA B
SEK 302.40
BioArctic
7D
1.2%
1Y
43.3%

BIOA B: China Alzheimer’s Access And Delivery Shift Will Drive Future Upside

Analysts are keeping their SEK 367.0 price target for BioArctic broadly unchanged, with only modest tweaks to underlying assumptions. They highlight parallels with recent bullish Street research on early stage biotech names that are seeing renewed interest around differentiated clinical assets.
MCOV B
SEK 206.50
Medicover
7D
-1.0%
1Y
6.4%

MCOV B: Dividend Uplift And 2028 Revenue Ambition Will Support Future Upside

Analysts have kept their price target for Medicover broadly unchanged at around SEK 257, reflecting stable assumptions on the discount rate, revenue growth, profit margin and future P/E multiples. What's in the News The board of Medicover AB proposes a dividend of SEK 0.20 per share for the financial year 2025, compared with SEK 0.15 previously, subject to approval at the annual general meeting on 29 April 2026 (Key Developments).
SOBI
SEK 372.80
Swedish Orphan Biovitrum
7D
-1.0%
1Y
27.7%

SOBI: Kidney And Sepsis Advances Will Support A More Upbeat Outlook

The analyst fair value estimate for Swedish Orphan Biovitrum has been adjusted from SEK 416 to SEK 424, reflecting recent price target increases to SEK 470 and SEK 500, as well as updated analyst views on revenue growth, margins and future P/E assumptions. Analyst Commentary Recent Street research on Swedish Orphan Biovitrum presents a mix of optimism and caution around the shares, which helps frame the updated fair value estimate of SEK 424.
EKTA B
SEK 56.10
Elekta
7D
-9.5%
1Y
-1.9%
BIOG B
SEK 113.40
BioGaia
7D
2.8%
1Y
-1.7%

BIOG B: Extra Dividend And Solid Margins Will Support Higher Earnings Multiple

Analysts have maintained their SEK 140.0 fair value estimate for BioGaia, citing only minor adjustments to the discount rate and to long-term assumptions on revenue growth, profit margins and future P/E as the basis for keeping their price target unchanged. What's in the News BioGaia renewed and extended its distribution agreement with Ewopharma, which will now distribute a broad range of BioGaia products in more than 15 European countries, with a focus on Central Eastern Europe and Switzerland (Key Developments).
VIMIAN
SEK 26.12
Vimian Group
7D
3.7%
1Y
-31.7%

VIMIAN: Reduced Price Outlook And Execution Risks Will Shape Fairly Balanced Prospects

Analysts have lowered their price target on Vimian Group to SEK 25 from SEK 27, reflecting updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E multiples. Analyst Commentary Bearish analysts have trimmed their fair value assumptions for Vimian Group, as seen in the reduced price target to SEK 25 from SEK 27.
ALIF B
SEK 139.30
AddLife
7D
-2.5%
1Y
-6.8%
CAMX
SEK 468.20
Camurus
7D
-2.6%
1Y
-22.7%

CAMX: Upcoming US And EU Launches Will Drive Future Upside Potential

Analysts have reset their price target on Camurus to SEK 930 from SEK 1,102, reflecting updated views on slightly higher forecast revenue growth, a modestly lower projected profit margin and a reduced future P/E multiple. What's in the News Camurus issued earnings guidance for 2026, expecting revenues of SEK 2.6b to SEK 2.9b and an operating result of SEK 0.9b to SEK 1.2b (Corporate guidance).
SANION
SEK 16.38
Saniona
7D
12.3%
1Y
143.8%
IMP A SDB
SEK 40.25
Implantica
7D
-5.3%
1Y
26.2%
DICOT
SEK 0.36
Dicot Pharma
7D
18.5%
1Y
42.2%

Is Dicot Pharma (STO:DICOT) In A Good Position To Invest In Growth?

Feb 03
Is Dicot Pharma (STO:DICOT) In A Good Position To Invest In Growth?